$240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment Company to host business strategy update conference call and webcast today at 4:30 PM ET Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using…
CidaraApril 24, 2024